Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis.
Academic Medical Centers
/ organization & administration
Biomarkers
/ metabolism
Clinical Trials, Phase I as Topic
/ methods
Drug Industry
/ organization & administration
Humans
Lupus Nephritis
/ epidemiology
National Institutes of Health (U.S.)
/ organization & administration
Preliminary Data
Public-Private Sector Partnerships
/ organization & administration
Sequence Analysis, RNA
/ methods
United States
/ epidemiology
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
29
04
2019
accepted:
03
09
2019
pubmed:
11
9
2019
medline:
6
5
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
The Accelerating Medicines Partnership (AMP) Lupus Network was established as a partnership between the National Institutes of Health, pharmaceutical companies, nonprofit stakeholders, and lupus investigators across multiple academic centers to apply high-throughput technologies to the analysis of renal tissue, urine, and blood from patients with lupus nephritis (LN). The AMP network provides publicly accessible data to the community with the goal of generating new scientific hypotheses and improving diagnostic and therapeutic tools so as to improve disease outcomes. We present here a description of the structure of the AMP Lupus Network and a summary of the preliminary results from the phase 1 studies. The successful completion of phase 1 sets the stage for analysis of a large cohort of LN samples in phase 2 and provides a model for establishing similar discovery cohorts.
Identifiants
pubmed: 31502417
doi: 10.1002/acr.24066
pmc: PMC6992476
mid: NIHMS1049429
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-242Subventions
Organisme : Pfizer
Pays : International
Organisme : NIAMS NIH HHS
ID : UH2 AR067681
Pays : United States
Organisme : Accelerating Medicines Partnership
Pays : International
Organisme : NIAMS NIH HHS
ID : UH2 AR067688
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067689
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067677
Pays : United States
Organisme : NIH HHS
ID : UH2-AR-067694
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067679
Pays : United States
Organisme : NIH HHS
ID : AR-069572
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
Pays : International
Organisme : Bristol-Myers Squibb
Pays : International
Organisme : NIAMS NIH HHS
ID : UH2 AR067685
Pays : United States
Organisme : NIAMS NIH HHS
ID : UM2 AR067678
Pays : United States
Organisme : Arthritis Foundation
Pays : International
Organisme : AbbVie
Pays : International
Organisme : Rheumatology Research Foundation
Pays : International
Organisme : Sanofi
Pays : International
Organisme : Lupus Foundation of America
Pays : International
Organisme : NIAMS NIH HHS
ID : UH2 AR067690
Pays : United States
Organisme : Lupus Research Alliance
Pays : International
Organisme : NIAMS NIH HHS
ID : UH2 AR067694
Pays : United States
Organisme : Merck Sharp & Dohme
Pays : International
Organisme : NIAMS NIH HHS
ID : UH2 AR067676
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067691
Pays : United States
Informations de copyright
© 2019, American College of Rheumatology.
Références
Lupus. 2014 Feb;23(2):159-65
pubmed: 24300780
Arthritis Rheumatol. 2019 Mar;71(3):403-410
pubmed: 30225916
Cell. 2015 May 21;161(5):1202-1214
pubmed: 26000488
Am J Kidney Dis. 1993 Apr;21(4):374-7
pubmed: 8465815
Arthritis Care Res (Hoboken). 2011 Jun;63(6):865-74
pubmed: 21309006
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Lupus. 2018 Jan;27(1):6-16
pubmed: 28474961
Cell. 2016 Jun 2;165(6):1548-1550
pubmed: 27259156
Arthritis Rheum. 1994 Mar;37(3):376-83
pubmed: 7510492
Pediatr Nephrol. 2019 Jan;34(1):117-128
pubmed: 30159624
Rheum Dis Clin North Am. 2014 Aug;40(3):537-52, ix
pubmed: 25034161
Nat Rev Genet. 2019 May;20(5):257-272
pubmed: 30696980
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Arthritis Rheumatol. 2016 Jun;68(6):1432-41
pubmed: 26815601
Rheumatology (Oxford). 2009 May;48(5):513-9
pubmed: 19286697
Semin Arthritis Rheum. 2018 Feb;47(4):545-551
pubmed: 28803673
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
J Invest Dermatol. 1963 Dec;41:451-6
pubmed: 14085466
Am J Ophthalmol. 2018 Feb;186:152-163
pubmed: 29246578
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75
pubmed: 17576678
Kidney Int. 2001 Nov;60(5):1893-903
pubmed: 11703608
Nat Immunol. 2019 Jul;20(7):915-927
pubmed: 31110316
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Med Phys. 2010 Jan;37(1):339-51
pubmed: 20175497
Adv Clin Chem. 2015;69:255-324
pubmed: 25934364
J Immunol. 2011 Feb 1;186(3):1849-60
pubmed: 21187439
JCI Insight. 2017 May 4;2(9):null
pubmed: 28469080
Nature. 2015 Jul 30;523(7562):612-6
pubmed: 26123020
J Rheumatol. 2012 Mar;39(3):510-5
pubmed: 22298906
Nat Immunol. 2019 Jul;20(7):902-914
pubmed: 31209404
Clin Immunol. 2017 Dec;185:10-20
pubmed: 27498110
Arthritis Rheum. 1997 Oct;40(10):1810-6
pubmed: 9336415
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923